Morning Notes : CPINV BB, CMBT BB, NN NA, MAAT FP

: CPINV BB, CMBT BB, NN NA, MAAT FP

MaaT Pharma Safety board recommends MaaT033 phase 2b continues as plan...

MaaT announced that the independent data safety monitoring board (DSMB) has completed the second pre-planned safety interim analysis of the ongoing randomised controlled phase 2b (PHOEBUS) trial of MaaT033 (microbiome therapy, oral capsule) in patients undergoing an allogeneic hematopoietic stem cell transplantation (allo-HSCT), and recommended that the study continue as planned. There were no safety concerns and no excessive mortality related to MaaT033 as of today. The upcoming routine DSMB re...

Life Sciences Conference 25 Sep 2025

KBC Securities will host its annual life sciences conference on 25 September in Brussels. The event will include 14 exciting companies, both public and private, from the BeNeLux ecosystem and beyond. In this conference note, we provide an overview of the attending companies, as well as an outlook on KBC Securities' life sciences broader coverage.

MaaT Pharma 1H25 results confirm timelines, runway to end Feb 2026

MaaT reported 1H25 results with € 2.4m in revenues from the early access program (1H24: € 1.7m) for MaaT013 in aGvHD, which points to increased demand for the product ahead of a potential EU approval in 2H26. Pipeline timelines were reiterated and we look forward to the final data from the phase 3 trial for MaaT013 in aGvHD for confirmation of the initial survival data reported in January 2025 (54% at 1-year). Beyond aGvHD, data from the phase 2 trial of MaaT013 in combination with ICI in metast...

Morning Notes : PNL NA, UCB BB, MAAT FP, DEME BB, SYENS BB

: PNL NA, UCB BB, MAAT FP, DEME BB, SYENS BB

ODDO BHF SECURITIES Small & MIDCAP MORNING NEWS – 09/12/2025

ODDO BHF SECURITIES Small & MIDCAP MORNING NEWS – 12/09/2025

Vetoquinol : H1 2025 results: sales in line, margins better than expec...

Vetoquinol : Résultats S1 25 : CA en ligne, marges meilleures qu’atten...

MaaT Pharma Secures € 37.5m tranched EIB financing

MaaT announced that it has secured a € 37.5m , 4-tranche financing from the European Investment Bank (EIB), which bears interest at 7%. In addition, MaaT will issue warrants to the EIB with each tranche. MaaT's previously communicated cash runway was into January 2026, which should now extend beyond that point following this additional funding, though we do note that disbursement of Tranches B to D is subject to operational and financing conditions, which we'd be keen to learn more about. All in...

Morning Notes : AALB NA, HNK1 NA, HKHHF NA, RETb BB, AZEb BB, MATPF FP

: AALB NA, HNK1 NA, HKHHF NA, RETb BB, AZEb BB, MATPF FP

Vetoquinol: 2 directors

Two Directors at Vetoquinol sold/bought 9,860 shares at 75.000EUR. The significance rating of the trade was 87/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...

Morning Notes : AED BB, AKZA NA, MAAT FP

: AED BB, AKZA NA, MAAT FP

MaaT Pharma Partnership with Clinigen secures MaaT013's EU commerciali...

MaaT signed a licensing, distribution, and commercial supply agreement with Clinigen in Europe for Xervyteg (MaaT013, microbiome therapy, enema formulation) in aGvHD for a € 10.5m upfront, € 18m in milestones, and mid-thirties flat royalty on sales. We believe this deal serves as validation of MaaT013's potential, and see the partnership as a de-risking event for MaaT013's commercialisation in Europe, given Clinigen's experience commercialising in haemato-oncology, with 3 products currently on t...

Morning Notes : VPK NA, MAAT FP, ZEAL DC

: VPK NA, MAAT FP, ZEAL DC

MaaT Pharma Business update highlights upcoming priorities, final ARES...

MaaT provides a business update, which reiterated the company's progress with respect to its pipeline, and following the previously announced EU regulatory submission for MaaT013 in aGvHD, the company continues to search for a commercialisation partner in Europe ahead of a potential approval in 2H26. Timeline for MaaT013 US trial launch shifts to 2026 (from 4Q25) to focus resources on the European opportunity. Looking ahead, data updates for MaaT013 in aGvHD (final results incl. 12-month OS), as...

MaaT Pharma Updated MaaT013 aGvHD EAP data at EHA shows consistent out...

MaaT reported updated early access program (EAP) results for MaaT013 (microbiome therapy, enema formulation) in aGvHD at EHA, being held 12-15 June. The data, which was previously shared in the abstract last month, shows that the response rates and overall survival observed in the steroid refractory and ruxulitinib resistant subset of patients (n=70) are in line with what was observed in the phase 3 ARES trial. In our view, this points to the consistency of outcomes with MaaT013 in this patient ...

Morning Notes : AGFB BB, BPOST BB, GLPG NA, PROX BB, UCB BB, MAAT FP

: AGFB BB, BPOST BB, GLPG NA, PROX BB, UCB BB, MAAT FP